Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies [Corrigendum]

Ailawadhi S, Biru Y, Clavreul S, et al. Patient Preference and Adherence 2025:19:1089–1104.

The authors have advised that Figure 5C on page 1099 contains an error. The reason provided in the second position “Too overwhelmed to commit to the option” should read “Patient has elected not to pursue any further treatment after multiple relapses”. The correct Figure 5 is as follows:

Figure 5 (A) Reasons why patients accepted BsAb therapy. (B) Reasons why HCPs did not offer BsAbs to all eligible patients with RRMM. (C) Reasons why patients declined BsAb therapy. Abbreviations: AE, adverse event; BsAb, bispecific antibody; EU, Europe; HCP, healthcare provider; RRMM, relapsed/refractory multiple myeloma. Notes: *Ex-US includes patients from Japan (n=7) and Europe (n=14); EU includes France, Germany, Italy, Spain, and the UK.

The authors apologize for this error.

Read the original article

© 2025 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.